SIM 1002

Drug Profile

SIM 1002

Alternative Names: SIM1002

Latest Information Update: 31 Aug 2009

Price : $50

At a glance

  • Originator Jiangsu Simcere Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 28 Mar 2006 Phase-II clinical trials in Viral infections in China (unspecified route)
  • 28 Mar 2006 Phase-II clinical trials in Bacterial infections in China (unspecified route)
  • 28 Mar 2006 SIM 1002 is available for partnering worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top